{
    "clinical_study": {
        "@rank": "23539", 
        "arm_group": [
            {
                "arm_group_label": "ASP8273 Dose Escalation cohort (part 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP8273 Response Expansion cohort (part 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP8273 and Midazolam RP2D Expansion cohort (part 2)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of ASP8273 and to\n      determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). This\n      study will also determine the pharmacokinetics (PK) of ASP8273 and evaluate the potential\n      inhibition of CYP3A4 by ASP8273 and the antitumor activity of ASP8273."
        }, 
        "brief_title": "A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-Small-Cell Lung Cancer (NSCLC)", 
            "Epidermal Growth Factor Receptor Mutations"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is composed of 2 parts: part 1 is the dose escalation phase and part 2 is the\n      recommended Phase 2 dose (RP2D) phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-child bearing potential or able to follow birth control requirements\n\n          -  Eastern Cooperative Oncology Group (ECOG) \u2264 1\n\n          -  Life expectancy \u2265 12 weeks\n\n          -  Laboratory criteria as:\n\n               -  Neutrophil count  \u2265 1,500/mm3\n\n               -  Platelet count \u2265 7.5 x 104 /mm3\n\n               -  Hemoglobin \u2265 9.0 g/dL\n\n               -  Lymphocyte count \u2265 500/mm3\n\n               -  Serum creatinine < 1.5 x institutional Upper Limit of Normal (ULN) or an\n                  estimated glomerular filtration rate (eGFR) of > 50 ml/min as calculated by the\n                  Modification of Diet in Renal Disease (MDRD) equation\n\n               -  Total bilirubin < 1.5 x ULN (except for subjects with documented Gilbert's\n                  syndrome)\n\n               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN\n\n          -  Dose escalation subjects: Epidermal Growth Factor Receptor (EGFR) activating mutation\n             by local testing: exon 18 G719X, exon 19 deletion, exon 21 L861Q, exon 21 L858R or\n             exon L861Q; and received prior treatment with EGFR Tyrosine Kinase Inhibitor (TKI)\n\n          -  Response expansion/RP2D expansion subjects: disease progression on prior EGFR TKI; no\n             anticancer treatment subsequent to EGFR TKI; activating mutation as above AND T790M\n             mutation; tumor sample subsequent to EGFR TKI is available for central testing; at\n             least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST)\n             1.1\n\n        Exclusion Criteria:\n\n          -  Any ongoing toxicity \u2265 Grade 2 attributable to prior Non-Small-Cell Lung Cancer\n             (NSCLC) treatment\n\n          -  Prior reversible EGFR inhibitor within 7 days; irreversible EGFR inhibitor or any\n             antitumor agent within 14 days; any investigational therapy within 28 days; blood\n             transfusion or hemopoietic factor within 14 days; major surgery within 14 days; any\n             strong CYP3A4 inhibitors within 7 days\n\n          -  Expansion cohorts only - subject has had prior treatment with an EGFR-T790M inhibitor\n             (CO-1686, AZD9291)\n\n          -  Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) or\n             Human Immunodeficiency Virus (HIV)\n\n          -  Symptomatic Central Nervous System (CNS) metastasis\n\n          -  Active infection requiring systemic therapy within 14 days\n\n          -  Severe or uncontrolled systemic diseases including uncontrolled hypertension\n\n          -  History of or active interstitial lung disease\n\n          -  Screening QTcF >450 msec or current medication known to prolong QT\n\n          -  \u2265 Grade 2 cardiac arrhythmia or uncontrolled atrial fib of any grade; Class 3 or 4\n             New York Heart Association congestive heart failure; history of severe/unstable\n             angina, myocardial infarction or cerebrovascular accident within 6 months\n\n          -  History of gastrointestinal ulcer or bleeding within 3 months; any digestive tract\n             dysfunction\n\n          -  Concurrent corneal disorder or ophthalmologic condition making subject unsuitable\n\n          -  RP2D cohort subjects: contraindications to midazolam, any other midazolam within 7\n             days, or any medications or supplements known to be strong CYP3A inhibitors within 7\n             days or inducers within 12 days\n\n          -  Any other malignancy requiring treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113813", 
            "org_study_id": "8273-CL-0102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP8273 Dose Escalation cohort (part 1)", 
                    "ASP8273 Response Expansion cohort (part 1)", 
                    "ASP8273 and Midazolam RP2D Expansion cohort (part 2)"
                ], 
                "description": "oral", 
                "intervention_name": "ASP8273", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP8273 and Midazolam RP2D Expansion cohort (part 2)", 
                "description": "oral", 
                "intervention_name": "midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Midazolam", 
                "Mitogens"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Non-Small-Cell Lung Cancer", 
            "NSCLC", 
            "Epidermal Growth Factor Receptor mutations", 
            "EGFR", 
            "ASP8273", 
            "Midazolam", 
            "irreversible EGFR inhibitor", 
            "T790M resistance mutation"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Virginia Cancer Specialists, PC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Swedish Cancer Institute Swedish Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations", 
        "overall_contact": {
            "email": "clintrials.info@us.astellas.com", 
            "last_name": "Astellas Pharma Global Development", 
            "phone": "800-888-7704", 
            "phone_ext": "5473"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Executive Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A DLT is defined as any pre-determined toxicity that is related to study drug per the investigator and which occurs during Cycle 0 and Cycle 1 using NCI CTCAE v4.03.", 
                "measure": "Safety and tolerability as assessed by Dose Limiting Toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 months"
            }, 
            {
                "description": "An AE is defined as any untoward medical occurrence in a subject administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", 
                "measure": "Safety and tolerability as assessed by adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 months"
            }, 
            {
                "description": "Laboratory tests to be conducted are hematology, biochemistry, urinalysis, coagulation profile, lipid panel and lymphocyte subpopulation.", 
                "measure": "Safety and tolerability as assessed by laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 months"
            }, 
            {
                "description": "Vital signs to be measured includes blood pressure, pulse rate and temperature.", 
                "measure": "Safety and tolerability as assessed by vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 months"
            }, 
            {
                "measure": "Safety and tolerability as assessed by 12-lead electrocardiograms (ECGs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum concentration (Cmax), the time after dosing when Cmax occurs (tmax), area under the concentration - time curve from time 0 up to the last quantifiable concentration (AUClast), area under the concentration - time curve from time 0 extrapolated to infinity (AUCinf), apparent terminal elimination half-life (t1/2), apparent oral systemic clearance (CL/F), Apparent volume of distribution (Vz/F)", 
                "measure": "Composite of pharmacokinetics of ASP8273 concentration and its metabolites (plasma): Cmax, tmax, AUClast, AUCinf, t1/2, CL/F, and Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycles 0-3, Day  8 and 15 of Cycle 1"
            }, 
            {
                "measure": "Composite of pharmacokinetics of midazolam concentration and its metabolites (plasma): Cmax, tmax, AUClast, AUCinf, t1/2, CL/F, and Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Day -1,  Day 1 of Cycle 2"
            }, 
            {
                "description": "Defined as proportion of subjects whose best overall response is Complete Response (CR) or Partial Response (PR) among all analyzed subjects.", 
                "measure": "Best overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "Defined as the proportion of subjects whose best overall response is rated as CR, PR or Stable Disease (SD) among all analyzed subjects.", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "description": "Defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed according to RECIST 1.1, whichever occurs first.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}